ライフサイエンスコーパス: Doxil

1 ercial liposomal formulation of doxorubicin (DOXIL).

2 v. injected pegylated liposomal doxorubicin (Doxil).

3 that of an equimolar dose of liposomal DOX (Doxil).

4 model of human hypersensitivity reactions to Doxil.

5 their combinations, including bortezomib and Doxil.

6 nical studies and by the clinical success of Doxil.

7 macromolecule-based cancer therapies such as Doxil.

8 bicin and its packaged liposomal formulation Doxil.

9 es C, 5 min) followed 30 min later with i.v. Doxil (1 mg) or Doxil alone.

10 f this combination for further evaluation is Doxil 30 mg/m(2) and docetaxel 60 mg/m(2) given every 3

11 When used with G-CSF, it is Doxil 30 mg/m(2) and docetaxel 75 mg/m(2) every 4 weeks.

12 G-CSF, the MTD was docetaxel 60 mg/m(2) and Doxil 30 mg/m(2) every 3 weeks; only 1 (7%) out of 15 pa

13 n treating the murine C26 colon carcinoma as Doxil, a commercial liposome doxorubicin formulation.

14 ared in the same size as Lip/Gd/DiI-DS, with Doxil, a liposomal drug of similar size used to treat se

15 Doxil, a liposomal formulation of the chemotherapeutic d

16 t given immediately before administration of Doxil, a liposomally encapsulated formulation of doxorub

17 umor ablation sharply increases intratumoral Doxil accumulation over i.v. Doxil alone, enabling a red

18 uggest that the injection of Doxebo prior to Doxil administration can help protect against Doxil-indu

19 d muscle loss compared with a single dose of Doxil alone and was as effective as free doxorubicin.

20 received direct injections of 1, 2, or 3 mg Doxil alone or in sequence with other agents directly in

21 es intratumoral Doxil accumulation over i.v. Doxil alone, enabling a reduction of systemic dose while

22 lowed 30 min later with i.v. Doxil (1 mg) or Doxil alone.

23 ouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter ((89)Zr-NRep) allo

24 egulatory science as applied to NEPs such as Doxil and can be adapted to the measurement of other NEP

25 o clinically useful cancer therapeutics like Doxil and DaunoXome.

26 dministered chemotherapeutic agents, such as Doxil and paclitaxel, thereby resulting in a profound an

27 stant (KB 8-5) tumor models compared to DOX, Doxil, and PEG5K-VE2/DOX.

28 New agents including doxorubicin, Doxil, and ricin mab35 are being developed to create a l

29 ntly higher levels of cytotoxicity over DOX, Doxil as well as PEG5K-VE2/DOX in PC-3 and 4T1.2 cells.

30 that pretreatment with a normalizing dose of Doxil can improve the efficacy of immune checkpoint inhi

31 vide evidence that the approved nanomedicine Doxil can induce normalization in a dose-dependent manne

32 To test the safety and effectiveness of Doxil chemomyectomy in monkey eyelids using treatment sc

33 Doxil chemomyectomy is an effective protocol to permanen

34 redicted based on the increase in intratumor Doxil concentration.

35 nanoparticle-based drug delivery platforms (Doxil, DaunoXome, Marqibo, and Abraxane) in the context

36 ise, the repeated injection of Doxebo before Doxil did not impact Doxil's pharmacokinetics in plasma

37 Higher doses of Doxil did not increase the desired myotoxic effect; appa

38 RF ablation reduced the i.v. Doxil dose needed to achieve intratumoral doxorubicin up

39 The effects of varying i.v. Doxil doses (0.0625-7.0 mg; n = 100) and the RF tip temp

40 Experiments were performed for Doxil, Doxil-like liposomes, and Doxil-like liposomes wi

41 ination with PEGylated liposomal doxorubicin/Doxil for ovarian cancer therapy.

42 Multiple cycles of intravenous c-JO4 plus Doxil (four cycles, 4 weeks apart, simulating the treatm

43 XIL only (n = 9); and (5) G5: IMP301 without DOXIL group as a control group (n = 4).

44 The cellular interaction with Doxil has slower uptake kinetics and the particles must

45 n clinically approved liposomal doxorubicin (Doxil) in HER2-overexpressing BT474 tumor xenograft mode

46 F) ablation with i.v. liposomal doxorubicin (Doxil) increases intratumoral doxorubicin accumulation a

47 (Doxebo) prior to Doxil treatment suppresses Doxil-induced complement activation-related pseudoallerg

48 oxil administration can help protect against Doxil-induced IR without adversely affecting treatment e

49 However, in order to use Doxebo to prevent Doxil-induced IR, we have to prove its safety and that i

50 All Doxil injections resulted in a significant loss of myofi

51 For the skin, Doxil is classified as an irritant rather than a vesican

52 ulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer ca

53 We found that Doxil kills more cancer cells, macrophages and neutrophi

54 atumoral penetration of a model nanocarrier (Doxil), leading to enhanced availability of the drug in

55 The combination of PDT and Doxil led to a highly significant potentiation in tumor

56 In contrast a 'Doxil'-like liposome formulation gave no such triggered

57 rformed for Doxil, Doxil-like liposomes, and Doxil-like liposomes with reduced cholesterol and pegyla

58 Experiments were performed for Doxil, Doxil-like liposomes, and Doxil-like liposomes with redu

59 an intravenous injection of doxorubicin-free Doxil-like PEGylated nano-liposomes (Doxebo) prior to Do

60 a greater amount of cell death in vivo after Doxil liposomes are administered.

61 Doxil liposomes are designed to retain doxorubicin in ci

62 ess the kinetics of doxorubicin leakage from Doxil liposomes.

63 Thus, repeated doses of Doxil may prove to be as clinically effective as free do

64 re examined histologically for the effect of Doxil on the orbicularis oculi muscle and the skin.

65 (3) G3: IMP301 + MB + LENS (n = 9); (4) G4: DOXIL only (n = 9); and (5) G5: IMP301 without DOXIL gro

66 ications for the mechanism of action, taking Doxil pharmacokinetics into account.

67 MRI detection of Lip/Gd coadministered with Doxil provided optimum CED parameters for complete cover

68 rked the new era of PEGylation, resulting in Doxil(R) (doxorubicin in PEGylated liposome) in 1995, Mo

69 The model was tested on DOXIL(R) (doxorubicin liposomes), and an excellent agree

70 c P85 was injected 1h, 48h, or 96h after the Doxil(R) administration in A2780 human ovarian cancer xe

71 posomes and increase therapeutic efficacy of Doxil(R) by administering Pluronic block copolymers once

72 e last decade of PEGylated nanodrugs such as Doxil(R) has seen a rise in the number of associated occ

73 uction in the deposition of both dextran and Doxil(R) in major organs with a concurrent increase in p

74 The antitumor efficacy of Doxil(R) is hindered by the poor release of the active d

75 mposition and size to be similar to those of Doxil(R) liposomes.

76 Furthermore, multifunctional immuno-Doxil(R) preparation showed increased cellular cytotoxic

77 est anti-tumor effect of single injection of Doxil(R) was achieved when Pluronic P85 was administered

78 l formulation of liposomal doxorubicin (i.e. DOXIL(R)) and were loaded with barbituric acid (BA), a s

79 -circulating liposomes (HSPC:cholesterol and Doxil(R)), modified with cell-penetrating TAT peptide (T

80 sustained DOX release, unlike overly stable Doxil(R), cellular uptake via multiple endocytosis pathw

81 ll survival, in comparison with free DOX and Doxil(R), especially upon repeated administrations.

82 are the preclinical and clinical results for Doxil(R), PK1, Abraxane(R), Genexol-PM(R), Xyotax, NC-60

83 pare them to DOX liposomes representative of DOXIL(R).

84 ds the overall survival of mice treated with Doxil(R).

85 nic P85 could facilitate release of Dox from Doxil(R).

86 when Pluronic P85 was administered 48h after Doxil(R).

87 Injection of Doxil resulted in significant reduction of skin injury c

88 was combined with the chemotherapeutic agent Doxil, resulting in some longer-term survivors.

89 ost or tumor, and it does not interfere with Doxil's antitumor activity in mice.

90 with Doxil treatment significantly increased Doxil's myotoxic effects.

91 prove its safety and that it does not affect Doxil's performance.

92 ection of Doxebo before Doxil did not impact Doxil's pharmacokinetics in plasma and therefore does no

93 As a potential alternative therapy, Doxil (Sequus, Menlo Park, CA), a liposome-encapsulated

94 ed 20 mg/m2 pegylated-liposomal doxorubicin (Doxil; Sequus Pharmaceuticals, Inc, Menlo Park, CA) ever

95 However, either two injections of Doxil spaced 2 months apart or preinjury of the lid with

96 ivalent milligram doses of free doxorubicin, Doxil spared the skin from injury.

97 +/- 7.7 microg/g) were seen with combined RF/Doxil therapy (P < 0.01).

98 greater tumor necrosis was identified for RF/Doxil-treated tumors compared with tumors treated with R

99 so found that macrophages and neutrophils in Doxil-treated tumours repopulated faster than cancer cel

100 ribution analysis on Doxorubicin-treated and Doxil-treated tumours to delineate the differences betwe

101 lid with bupivacaine before a single dose of Doxil treatment resulted in increased muscle loss compar

102 s using the preinjury protocol combined with Doxil treatment significantly increased Doxil's myotoxic

103 e PEGylated nano-liposomes (Doxebo) prior to Doxil treatment suppresses Doxil-induced complement acti

104 cetaxel 75 mg/m(2) every 4 weeks, the MTD of Doxil was 30 mg/m(2) and required granulocyte colony-sti

105 Doxil was only approximately 60% as effective in killing

106 Bupivacaine/hyaluronidase and Doxil were injected sequentially into the eyelids of fiv

107 Although single injections of Doxil were myotoxic, multiple exposure of the eyelid to

108 Infusion reactions were common with Doxil with the recommended infusion schedule during the